Natixis Sorrento Therapeutics, Inc. Transaction History

Natixis

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.51 - $2.88 $33,441 - $63,783	22,147 Added 147.65%	37,147 $60,000
Q2 2022 Aug 12, 2022	SELL	$1.24 - $2.33 $53,109 - $99,793	-42,830 Reduced 74.06%	15,000 $30,000
Q1 2022 May 13, 2022	BUY	$2.0 - $4.9 $84,200 - $206,290	42,100 Added 267.64%	57,830 $135,000
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.23 $73,144 - $113,727	15,730 New	15,730 $73,000
Q2 2021 Aug 13, 2021	SELL	$6.35 - $10.0 $67,945 - $107,000	-10,700 Closed	0 $0

Q1 2021 May 14, 2021	SELL	$7.03 - $16.51 $2.12 Million - $4.97 Million	-301,100 Reduced 96.57%	10,700 $88,000
Q4 2020 Feb 12, 2021	BUY	$5.76 - $11.95 $1.52 Million - $3.14 Million	263,040 Added 539.46%	311,800 $2.13 Million
Q3 2020 Nov 12, 2020	BUY	$6.17 - $18.82 $300,849 - $917,663	48,760 New	48,760 $544,000

5.51M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.